All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bruton Tyrosine Kinase (BTK) inhibitors inhibit the enzyme BTK, which plays a crucial role in oncogenic signaling and interactions with tumour microenvironment, critical for proliferation and survival of malignant B cells. Examples of BTK inhibitors include ibrutinib, zanubrutinib, and acalabrutinib.
Save to your areas of interest